Indeed, when combined with cetuximab, the CDK4/6 inhibitor palbociclib has shown clinical efficacy in HNSCC in a phase I trial [40] and a multicenter phase II trial [41]. Here, CDK4 is linked to head and neck squamous cell carcinoma.